FDA approves first drug for full range of narcolepsy symptoms

The U.S. Food and Drug Administration has granted approval to Orzeyful (oveporexton) tablets, marking the first medication approved for the comprehensive treatment of narcolepsy type 1 in adults. This breakthrough drug directly addresses the loss of orexin signaling, a key factor in causing the disease. Orzeyful's approval stems from two randomized, double-blind, placebo-controlled studies involving 273 adults with narcolepsy type 1.

Over a 12-week period, patients receiving Orzeyful (at 2 mg) demonstrated significant improvements in daytime wakefulness compared to those taking placebo. Additionally, the drug led to substantial reductions in cataplexy episodes, as well as notable enhancements in sleep paralysis, hallucinations, and disrupted nighttime sleep.

The most frequently reported side effects included insomnia, urinary symptoms, urgency to urinate, and increased saliva production. Tiffany R. Farchione, MD, from the FDA Center for Drug Evaluation and Research, emphasized the importance of this development, stating that for too long, individuals with narcolepsy type 1 have had to rely on treatments that only partially address their complex, lifelong neuropsychiatric condition.

Orzeyful, developed by Takeda Pharmaceuticals, is now the first medicine to target the underlying biology of the disease, offering a more holistic approach to treating narcolepsy type 1.